Perampanel疗效和耐受性enzyme-inducing aed的癫痫患者

Treatment response in completers by actual (last) perampanel dose (studies 304, 305, and 306) (A) Median percent reduction in seizure frequency per 28 days from baseline over double-blind period. (B) Responder rate during maintenance period. Excludes patients from Central and South America and perampanel 6 and 10 mg. EIAEDs include carbamazepine, oxcarbazepine, or phenytoin. ^aOverall placebo is shown in graph; actual placebo median percent reduction in seizure frequency for each dose group was used for statistical analysis (EIAED placebo: 2 mg = 10.1, 4 mg = 10.1, 8 mg = 8.7, 12 mg = 5.8; non-EIAED placebo: 2 mg = 12.7, 4 mg = 12.7, 8 mg = 15.3, 12 mg = 15.9). ^bOverall placebo is shown in graph; actual placebo responder rate for each dose group was used for statistical analysis (EIAED placebo: 2 mg = 18.1, 4 mg = 18.1, 8 mg = 19.4, 12 mg = 20.6; non-EIAED placebo: 2 mg = 19.4, 4 mg = 19.4, 8 mg = 17.1, 12 mg = 15.0). *p < 0.05; **p < 0.01 vs placebo for each dose; †p < 0.05; ‡p < 0.005 EIAEDs vs non-EIAEDs for each dose based on rank analysis of covariance (for median percent reduction) and χ² test (responder rate). EIAED = enzyme (CYP3A4)-inducing antiepileptic drug; N = number of patients in each group.